PAOG Highlights Its Own Cannabis Pharma Tech As GWPH Valued At $7.2 B
February 03 2021 - 10:32AM
InvestorsHub Cannabis NewsWire
Sandusky, OH -- February 3, 2021 -- InvestorsHub
NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today highlighted its own proprietary, U.S. Patent
backed, cannabis pharmaceutical technology in light of the
announcement today that Jazz
Pharmaceuticals (JAZZ) plans to purchase GW Pharmaceuticals (GWPH)
for $7.2 billion.
Last year, PAOG
acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx
is a cannabis treatment under development for Chronic Obstructive
Pulmonary Disorder (COPD) derived from a patented cannabis
extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND
APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE
CANNABIS PLANT."
PAOG recently
announced an engagement with Veristat, Inc., a contract research
organization headquartered in Southborough, Massachusetts. PAOG has
engaged Veristat to assist in advancing PAOG with its proprietary
Cannabidiol (CBD) extract for the treatment of Chronic Obstructive
Pulmonary Disorder (COPD) toward initiating an Investigational New
Drug application (IND) with the Food and Drug Administration
(FDA).
PAOG management
anticipates a pharmaceutical development process to be a long-term
endeavor. Management is committed to pursuing complimentary
initiatives that have the potential to deliver revenue and profit
in a shorter time frame.
PAOG has also
recently engaged with the Puerto Rico Consortium for Clinical
Investigation to assist PAOG with developing its proprietary
Cannabidiol (CBD) extract into a nutraceutical product to provide
care for those experiencing issues associated with Chronic
Obstructive Pulmonary Disorder
(COPD).
Earlier today, PAOG announced the company
anticipates reporting an estimated $50,000 in revenue for Q4
2020.
The
revenue is anticipated from a $300,000 sales agreement executed by
PAOG’s cannabis cultivation subsidiary.
Last summer, PAOG acquired a cannabis
cultivation business from Puration, Inc. (USOTC:
PURA). The acquisition was made in conjunction with
PAOG’s overall cannabis pharmaceuticals
strategy.
Learn more about PAOG
at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2023 to Aug 2024